Abeona Signs Exclusive License Agreement with Regenxbio to Develop and Commercialize NAV AAV9 vector

 Abeona Signs Exclusive License Agreement with Regenxbio to Develop and Commercialize NAV AAV9 vector

Abeona Signs Exclusive License Agreement with Regenxbio to Develop and Commercialize NAV AAV9 vector

Shots:

  • Regenxbio to get $100M as total deal value plus $20M upfront ($10M paid on signing, $10M with 12 mos.) in addition to $60M milestone payment on sales
  • Abeona to hold exclusive WW rights of Regenxbio’s NAV AAV9 vector, to develop gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 and CLN3
  • Regenxbio’s NAV AAV9 vector is based on its NAV Technology Platform indicated for the treatment of systemic and CNS manifestations

Click here to read full press release/ article | Ref: Regenxbio | Image: Orphan Disease Center

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post